Results 11 to 20 of about 2,052,688 (283)

Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular Cloning

, 2022
Strategies in Chimeric Antigen Receptor & T Cell Receptor Design & Molecular ...
Anthony J Bais (13285305)
core   +1 more source

Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]

, 2012
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor, Johannessen, Ingolfur, Talbot, Simon, Cheadle, Eleanor J, Crawford, Dorothy, Gilham, David, Gilham, David E, Johannessen, Ingo, Swanson, Anna   +8 more
core   +1 more source

An Interesting Similarity of Bacillus Calmette-Guerin and Chimeric Antigen Receptor T Cells

Translational Research in Urology, 2020
Intravesical Bacillus Calmette-Guerin (BCG) is approved for non-muscle invasive bladder cancer treatment a long time ago. Chimeric antigen receptor T cells (CAR-Tcell), are T cells are genetically engineered T cells that produce an artificial T-cell ...
Seyed Saeed Tamehri Zadeh, AhmadReza Rezaeian   +1 more
doaj   +1 more source

Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy—A Case Report

Critical Care Explorations, 2021
BACKGROUND:. Chimeric antigen receptor T-cell therapies (CAR-T) are transforming the treatment of B-cell leukemias and lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent common, potentially life ...
Kai Singbartl, MD, MPH, Allison Rosenthal, DO, Jose Leis, MD, PhD, Bhavesh Patel, MD, Ayan Sen, MD, MSc   +4 more
doaj   +1 more source

Engineering Chimeric Antigen Receptors [PDF]

Acta Naturae, 2017
Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the development and optimization of new CAR T cells directed against a broad range of target antigens.
S V, Kulemzin, V V, Kuznetsova, M, Mamonkin, A V, Taranin, A A, Gorchakov   +4 more
openaire   +2 more sources

CAR-T cell therapy for hematological malignancies: History, status and promise

Heliyon, 2023
For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis.
Chao Wang, Jianpeng Wang, Shusheng Che, Hai Zhao   +3 more
doaj   +1 more source

Global Manufacturing of CAR T Cell Therapy

Molecular Therapy: Methods & Clinical Development, 2017
Immunotherapy using chimeric antigen receptor-modified T cells has demonstrated high response rates in patients with B cell malignancies, and chimeric antigen receptor T cell therapy is now being investigated in several hematologic and solid tumor types.
Bruce L. Levine, James Miskin, Keith Wonnacott, Christopher Keir   +3 more
doaj   +1 more source

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

Frontiers in Immunology, 2018
Adoptive cell therapy has emerged as a powerful treatment for advanced cancers resistant to conventional agents. Most notable are the remarkable responses seen in patients receiving autologous CD19-redirected chimeric antigen receptor (CAR) T cells for ...
Rohtesh S. Mehta, Katayoun Rezvani
doaj   +1 more source

Supplementary Data from Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid Tumors

, 2022
Supplementary Data from Targeted Rejuvenation of Exhausted Chimeric Antigen Receptor T Cells Regresses Refractory Solid ...
Xin Liu (15098717), Boning Zhang (5209397), Qian Luo (610818), John V. Napoleon (12093653), Philip S. Low (15098720), Suilan Zheng (2389246)   +5 more
core   +1 more source

CAR-T Therapy in Lymphoma Patients With Coexisting Cardiomyopathy or Cardiac Lymphomatous Involvement

JACC: Case Reports, 2023
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the management of aggressive hematologic malignancies. However, its role in patients with lymphoma and cardiac metastasis or cardiomyopathy remains undefined due to potentially life ...
Choon Ta Ng, MBBS, Hilda M. Gonzalez Bonilla, MD, Ian Chang, MD, M. Tun Aung, MD, Jennifer J. Gile, MD, Naveen L. Pereira, MD, Jose C. Villasboas Bisneto, MD, Patrick B. Johnston, MD, Hector R. Villarraga, MD, Martin G. Rodriguez-Porcel, MD, Grace Lin, MD, Yi Lin, MD, PhD, Joerg Herrmann, MD   +12 more
doaj   +1 more source